Search

Displaying results 5881 - 5890 of 7895 in total
  1. Drug

    5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole

    go.drugbank.com/drugs/DB08721
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole targets … 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole is a solid. This compound belongs to the phenol ethers.

  2. Drug

    5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08728
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. … 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers.

  3. Drug

    Ramosetron

    go.drugbank.com/drugs/DB09290
    Investigational

    It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron. … Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions.

  4. Drug

    Radequinil

    go.drugbank.com/drugs/DB19722
    Investigational

    Radequinil is a small molecule drug. The usage of the INN stem '-nil' in the name indicates that Radequinil is a benzodiazepine receptor antagonist/agonist. … Radequinil has a monoisotopic molecular weight of 334.11 Da.

  5. Drug

    Solcitinib

    go.drugbank.com/drugs/DB19856
    Investigational

    Solcitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Solcitinib is a Janus kinase inhibitor. … Solcitinib has a monoisotopic molecular weight of 389.19 Da.

  6. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  7. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  8. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure. … A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  10. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload."